-
September 2022
The September newsletter featured several recent press releases from the ACTG and a piece about the TB TSG member-in-training program.…
-
July 2022
The July newsletter featured a number of ACTG updates, including a piece announcing the renaming of UW CRS to become…
-
June 2022
The June newsletter featured two pieces in honor of HIV Long Term Survivors Awareness Day (June 5), written by ACTG…
-
May 2022
The May newsletter announced the initiation of study A5383, a clinical trial evaluating whether the anti- cytomegalovirus (CMV) drug letermovir…
-
April 2022
The April newsletter announced the FDA approval of the investigational new drug application for S-217622, a novel COVID oral antiviral…
-
March 2022
The March newsletter featured a recap of the ACTG’s oral and poster presentations at CROI 2022 and announced Dr. Sukhulile…
-
February 2022
The February newsletter announced the first participant randomized to A5386, a phase 1 HIV cure study evaluating two promising therapies…
-
January 2022
The January newsletter announced the recipients of the 2021 Tuberculosis Transformative Science Group Special Contributions award (Drs. Nishi Suryavanshi and…
-
December 2021
he December newsletter features a tribute to Dr. Scott Hammer, who passed away last month. In honor of World AID…
-
November 2021
The November newsletter announced the new leadership of the transformative science groups and the enrollment for A5404. The newsletter featured…
-
October 2021
The October newsletter announced the graduation of the novel polyclonal antibody therapy, SAB-185 to the phase 3 study of ACTIV-2…
-
September 2021
The September newsletter announced the positive data for the monoclonal antibody combination therapy BRII196/BRII-198 from the ACTIV-2 study. The newsletter…